Karakterizacija sojeva Streptococcus pneumoniae izolovanih od pacijenata sa meningitisom pre uvođenja pneumokokne konjugovane vakcine u Srbiji
Scindeks Asistent Scindeks Asistent — Sistem za uređivanje časopisa
PDF

Kako citirati

1.
Milojević SD, Kekić D, Gajić I, Mijač V, Opavski N. Karakterizacija sojeva Streptococcus pneumoniae izolovanih od pacijenata sa meningitisom pre uvođenja pneumokokne konjugovane vakcine u Srbiji. MedPodml [Internet]. 17. Juni 2020. [citirano 12. Juli 2026.];71(2):39-45. Dostupno na: https://asistent.ceon.rs/index.php/medpod/article/view/22252

Sažetak

Bakterijski meningitis je teško oboljenje koje je najčešće izazvano pneumokokom i javlja se obično kod dece ≤ 2 godine, kao i osoba ≥ 65 godina. Iskustvo iz zemalja koje su uvele pneumokoknu konjugovanu vakcinu (PCV) je pokazalo da je došlo do značajnog pada incidencije pneumokoknog meningitisa, izmene distribucije serotipova i smanjenja rezistencije na antibiotike. U Srbiji je u aprilu 2018. uvedena obavezna imunizacija dece PCV. Kako bi se mogao pratiti efekat PCV neophodno je imati podatke o sojevima u prevakcinalnoj eri. Ovaj rad  ispituje distribuciju serotipova,  pokrivenost cirkulišućih serotipova PCV, kao i osetljivost na antibiotike pneumokoka izolovanih od pacijenata sa meningitisom u prevakcinalnom periodu Srbije. Rezultati ovog rada predstavljaju polaznu osnovu za praćenje efekata PCV u Srbiji.

DOI: 10.5937/mp71-22252

Reference

(1) Murray P, Rosenthal K, Pfaller M. Medical Microbiology: Streptococcus and Enterococcus. ed. 8. Philadelphia: Elsevier; 2016.

(2) European Centre for Disease Prevention and Control. Invasive pneumococcal disease. In: ECDC. Annual epidemiological report for 2016. Stockholm: ECDC; 2018. dostupno na sajtu: https://ecdc.europa.eu/en/publications-data/invasive-pneumococcal-disease-annual-epidemiological-report-2016

(3) Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev. 2010 Jul; 23(3): 467-492.

(4) Dimitrijević D, Drakulović M, Milinković M, Plavša D, Simić D, Stošić M. et al. Izveštaj o zaraznim bolestima u Republici Srbiji za 2017. godinu: Bakterijski meningitisi (Meningitis bacterialis). Beograd: Institut za javno zdravlje Srbije „Milan Jovanović Batut“; 2018.

(5) Geno KA, Gilbert GL, Song JY, Skovsted, IC, Klugman KP, Jones C. et al. Pneumococcal capsules and their types: past, present and future. Clin Microbiol Rev. 2015 Jun; 28(3): 871-899.

(6) Cherazard R, Epstein M, Doan TL, Salim T, Bharti S, Smith MA. Antimicrobial resistant Streptococcus pneumoniae: prevalence, mechanisms, and clinical Implications. Am J Ther. 2017 May; 24(3): 361-369.

(7) Silva-Costa C, Brito M, Aguiar S, Lopes JP, Ramirez M, Melo-Cristino J. et al. Dominance of vaccine serotypes in pediatric invasive pneumococcal infections in Portugal (2012–2015). Sci Rep – Nature. 2018 Jan; 8(1): 1-9.

(8) Tin Tin Htar M, Christopoulou D, Schmitt HJ. Pneumococcal serotype evolution in Western Europe. BMC Infect Dis. 2015 Sep; 15(1): 419-429.

(9) The European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters. Version 8.0, 2018. dostupno na sajtu: http://www.eucast.org/clinical_breakpoints/

(10) Vergison A, Tuerlinckx D, Verhaegen J, Malfroot A. Epidemiologic features of invasive pneumococcal disease in Belgian children: passive surveillance is not enough. Pediatrics. 2006 Oct; 118(3): 801-809.

(11) Müller Premru M, Beović B, Pokorn M, Cvitković Špik V. Serotypes and genotype of invasive pneumococci in the central part of Slovenia. Wien Klin Wochenschr. 2015 Sep; 127(1): 691-695.

(12) Guzvinec M, Tesović G, Tambić-Andrasević A, Zidovec-Lepej S, Vukić BT, Begovac J. The epidemiology of invasive Streptococcus pneumoniae disease in Croatian children. Med Sci Monit. 2008 Apr; 14(4): 59-64.

(13) Weinberger R, von Kries R, van der Linden M, Rieck T, Siedler A, Falkenhorst G. Invasive pneumococcal disease in children under 16 years of age: Incomplete rebound in incidence after the maximum effect of PCV13 in 2012/13 in Germany. Vaccine. 2018 Jan; 36(4): 572-577.

(14) The European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019. dostupno na sajtu: http://www.eucast.org/clinical_breakpoints/

(15) Kim L, McGee L, Tomczyk S, Beall B. Biological and epidemiological features of

antibiotic-resistant Streptococcus pneumoniae in pre- and post-conjugate vaccine

eras: a United States perspective. Clin Microbiol Rev. 2016 Apr; 29(3): 525-552.

(16) Hadnađev M, Gajić I, Mijač V, Kurucin T, Považan A, Opavski N. et al. Phenotypes and genotypes of macrolide-resistant Streptococcus pneumoniae in Serbia. Arch Biol Sci. 2014; 66(1): 99-105.

(17) Maraki S, Mantadakis E, Samonis G. Serotype distribution and antimicrobial resistance of adult Streptococcus pneumoniae clinical isolates over the period 2001-2008 in Crete, Greece. Chemotherapy. 2010 Aug; 56(4): 325-332.

(18) Torumkuney D, Nica M, Nistor I, Morrissey I. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Bulgaria, Romania, Serbia and Croatia. J Antimicrob Chemother 2018 Apr; 73(5): 2-13.

(19) Luminos M, Dorobat O, Jugulete G. Popescu GA. Nasopharyngeal carriage of Streptococcus pneumoniae in Romanian children before the introduction of the pneumococcal conjugated vaccination into the national immunization programme: a national, multi-centre, cross-sectional observational study. Int J Infect Dis. 2014 Oct; 29C(C): 169-173.

(20) Isturiz R, Sings H, Hilton B Reinert RR, Jodar L. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert Rev Vaccines. 2017 Jul; 16(10): 1007-1027.